دورية أكاديمية
أعرض في EDS

Ozone Therapy in the Integrated Treatment of Female Dogs with Mammary Cancer: Oxidative Profile and Quality of Life.

التفاصيل البيبلوغرافية
العنوان: Ozone Therapy in the Integrated Treatment of Female Dogs with Mammary Cancer: Oxidative Profile and Quality of Life.
المؤلفون: Silva LP; Research Center on Mammary Oncology (NPqOM), Federal University of Bahia, Salvador 40170-110, Brazil., Portela RW; Laboratory of Immunology and Molecular Biology (LABIMUNO), Institute of Health Sciences, Federal University of Bahia, Salvador 40110-100, Brazil., Machado MC; Research Center on Mammary Oncology (NPqOM), Federal University of Bahia, Salvador 40170-110, Brazil.; Center for Agricultural, Environmental and Biological Sciences, Federal University of Reconcavo of Bahia, Cruz das Almas 44380-000, Brazil., Canuto GAB; Department of Analytical Chemistry, Institute of Chemistry, Federal University of Bahia, Salvador 40170-110, Brazil., Costa-Neto JM; Research Center on Mammary Oncology (NPqOM), Federal University of Bahia, Salvador 40170-110, Brazil.; Department of Anatomy, Pathology and Veterinary Clinics, Federal University of Bahia, Salvador 40170-110, Brazil., Carvalho VMP; Research Center on Mammary Oncology (NPqOM), Federal University of Bahia, Salvador 40170-110, Brazil., Sá HC; Department of Analytical Chemistry, Institute of Chemistry, Federal University of Bahia, Salvador 40170-110, Brazil., Damasceno KA; Research Center on Mammary Oncology (NPqOM), Federal University of Bahia, Salvador 40170-110, Brazil.; Experimental Pathology Laboratory (LAPEX), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador 40296-710, Brazil., Souza VRC; Faculty of Veterinary Medicine, Lusofona University, 1749-024 Lisbon, Portugal., Coelho CS; Faculty of Veterinary Medicine, Lusofona University, 1749-024 Lisbon, Portugal.; Veterinary and Animal Research Centre (CECAV), Faculty of Veterinary Medicine, Lusofona University, 1749-024 Lisbon, Portugal.; Mediterranean Institute for Agriculture, Environment and Development, Universidade de Évora, 7004-516 Évora, Portugal., Estrela-Lima A; Research Center on Mammary Oncology (NPqOM), Federal University of Bahia, Salvador 40170-110, Brazil.; Department of Anatomy, Pathology and Veterinary Clinics, Federal University of Bahia, Salvador 40170-110, Brazil.
المصدر: Antioxidants (Basel, Switzerland) [Antioxidants (Basel)] 2024 May 30; Vol. 13 (6). Date of Electronic Publication: 2024 May 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101668981 Publication Model: Electronic Cited Medium: Print ISSN: 2076-3921 (Print) Linking ISSN: 20763921 NLM ISO Abbreviation: Antioxidants (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2012]-
مستخلص: Considering the high frequency of malignant breast tumors, there is a growing search for new therapeutic strategies that control neoplastic growth and dissemination, combined with fewer adverse reactions. Therefore, this study evaluated the effects of ozone therapy in female dogs with mammary cancer undergoing chemotherapy treatment. Twenty-five canines diagnosed with malignant mammary neoplasia were divided into two groups: one treated with carboplatin alone ( n = 11) and the other with carboplatin associated with ozone therapy ( n = 14). Clinical and laboratory evaluations, mastectomy, analysis of the oxidative profile based on total antioxidant capacity (TAC) and serum concentrations of malondialdehyde (MDA), survival rate, and quality of life were performed. Animals in the ozone therapy group had higher concentrations of red blood cells and platelets, significantly improving the survival rate and quality of life. Furthermore, adverse reactions were less intense and frequent in this group, which was associated with an increase in TAC and a reduction in MDA. These results indicate that the combination of carboplatin and ozone therapy represents a promising complementary treatment for female dogs with mammary cancer, as it was associated with fewer adverse reactions and a better oxidative profile.
References: Toxicol Pathol. 2010 Jan;38(1):96-109. (PMID: 20019356)
Antioxidants (Basel). 2019 Nov 26;8(12):. (PMID: 31779159)
Cancer Treat Rev. 2018 Sep;69:243-253. (PMID: 30121504)
Arch Physiol Biochem. 2018 May;124(2):171-174. (PMID: 28871825)
Animals (Basel). 2022 Nov 10;12(22):. (PMID: 36428336)
Vet Comp Oncol. 2021 Jun;19(2):311-352. (PMID: 33427378)
J Carcinog. 2006 May 11;5:14. (PMID: 16689993)
Nat Rev Dis Primers. 2019 Sep 23;5(1):66. (PMID: 31548545)
Int J Mol Sci. 2021 Mar 10;22(6):. (PMID: 33802143)
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241226667. (PMID: 38258533)
Mediators Inflamm. 1999;8(4-5):205-9. (PMID: 10704074)
Blood. 2005 Jan 15;105(2):659-69. (PMID: 15374877)
Bio Protoc. 2019 Jun 20;9(12):e3263. (PMID: 33654783)
Vet Anim Sci. 2021 Jul 28;13:100191. (PMID: 34401601)
Free Radic Biol Med. 2018 Aug 20;124:114-121. (PMID: 29864481)
Clin Biochem. 2004 Apr;37(4):277-85. (PMID: 15003729)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Respir Physiol Neurobiol. 2023 Jan;307:103979. (PMID: 36243292)
Angew Chem Int Ed Engl. 2019 Oct 7;58(41):14758-14763. (PMID: 31429173)
Evid Based Complement Alternat Med. 2019 Nov 18;2019:2169103. (PMID: 31827546)
Int J Clin Exp Med. 2015 Aug 15;8(8):13303-9. (PMID: 26550257)
J Comp Pathol. 2022 Jan;190:1-12. (PMID: 35152966)
J Cancer Res Clin Oncol. 2009 Aug;135(8):997-1004. (PMID: 19125297)
CA Cancer J Clin. 2019 Nov;69(6):438-451. (PMID: 31577379)
Evid Based Complement Alternat Med. 2015;2015:480369. (PMID: 26357522)
Biomed Chromatogr. 2010 Aug;24(8):908-13. (PMID: 20041399)
Biology (Basel). 2023 Dec 11;12(12):. (PMID: 38132338)
Evid Based Complement Alternat Med. 2022 Jan 15;2022:8528938. (PMID: 35075366)
Comp Immunol Microbiol Infect Dis. 2019 Dec;67:101351. (PMID: 31525571)
Adv Chronic Kidney Dis. 2021 Sep;28(5):402-414.e1. (PMID: 35190107)
J Interv Med. 2022 May 21;5(2):64-71. (PMID: 35936665)
Clin Hemorheol Microcirc. 2019;71(3):365-372. (PMID: 29914015)
Int J Environ Res Public Health. 2023 Jan 13;20(2):. (PMID: 36674232)
Evid Based Complement Alternat Med. 2018 Sep 09;2018:7931849. (PMID: 30271455)
J Biol Chem. 2009 Jun 19;284(25):16767-16775. (PMID: 19386601)
J Biol Regul Homeost Agents. 1994 Oct-Dec;8(4):108-12. (PMID: 7660851)
J Clin Pathol. 1993 Feb;46(2):189-90. (PMID: 8459046)
Antioxidants (Basel). 2021 Dec 04;10(12):. (PMID: 34943049)
J Transl Med. 2011 May 17;9:66. (PMID: 21575276)
Clin Cancer Res. 2014 Aug 15;20(16):4289-301. (PMID: 24944316)
BMC Vet Res. 2013 May 11;9:101. (PMID: 23663727)
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8030-8033. (PMID: 30536352)
J Am Vet Med Assoc. 2005 Apr 15;226(8):1354-8. (PMID: 15844428)
In Vivo. 2012 May-Jun;26(3):375-9. (PMID: 22523289)
Vet Res Commun. 2005 May;29(4):287-96. (PMID: 15751580)
Biology (Basel). 2018 Jan 11;7(1):. (PMID: 29324687)
Crit Rev Oncol Hematol. 2017 Aug;116:89-98. (PMID: 28693803)
J Small Anim Pract. 1999 Jul;40(7):326-31. (PMID: 10444752)
Cancers (Basel). 2020 Sep 27;12(10):. (PMID: 32992648)
Eur J Pharmacol. 2014 Nov 5;742:158-62. (PMID: 25218903)
Res Vet Sci. 2020 Jun;130:240-246. (PMID: 32234614)
J Biomed Res. 2012 May;26(3):185-92. (PMID: 23554748)
Vet Comp Oncol. 2020 Dec;18(4):804-810. (PMID: 32452107)
PLoS One. 2018 Oct 4;13(10):e0204830. (PMID: 30286124)
معلومات مُعتمدة: Research Fellowship to Alessandra Estrela (Proc. 310058/2022-8) National Council for Scientific and Technological Development; Technological Development Fellowship to Ricardo Portela (Proc. 310058/2022-8) National Council for Scientific and Technological Development; PhD Fellowship to Lais Silva Coordenação de Aperfeicoamento de Pessoal de Nível Superior
فهرسة مساهمة: Keywords: breast cancer; chemotherapy-induced side effects; integrative medicine; ozone; reactive oxygen species
تواريخ الأحداث: Date Created: 20240627 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11200475
DOI: 10.3390/antiox13060673
PMID: 38929112
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-3921
DOI:10.3390/antiox13060673